New directions in the treatment of anxiety disorders

Bibliography

• KESSLER RC, MCGONAGLE KA, ZHAO S et al.: Lifetime and, 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiatry (1994) 51:8–19.
   PubMed Web of Science ®Google Scholar
• •Epidemiological study considered the best estimation of the prevalence of anxiety disorders in the general population.
   Google Scholar
• MARKOWITZ JS, WEISSMAN MM, OUELLETTE R, LISH JD, KLERMAN GL: Quality of life in panic disorder. Arch. Gen. Psychiatry (1989) 46:984–992.
   PubMed Web of Science ®Google Scholar
• WEISSMAN MM: Panic disorder: impact on quality of life. J. Clin. Psychiatry (1991) 52 (Supp1.9):6–8.
   Google Scholar
• CANDILIS PJ, MCLEAN RY, OTTO MW et al.: Quality of life in patients with panic disorder. J. Nerv. Ment. Dis. (1999) 187:429–434.
   PubMedGoogle Scholar
• TARLOV AR, WARE JE, JR., GREENFIELD S, NELSON EC, PERRIN E, ZUBKOFF M: The Medical Outcomes Study. An application of methods for monitoring the results of medical care. JAMA (1989) 262:925–930.
   Google Scholar
• CANDILIS PJ, POLLACK MH: The hidden costs of untreated anxiety disorders. Han'. Rev. Psychiatry (1997) 5:40–42.
   PubMed Web of Science ®Google Scholar
• WOODS JH, KATZ JL, WINGER G: Benzodiazepines: use,abuse and consequences. Pharmacol. Rev. (1992) 44:151–347.
   PubMed Web of Science ®Google Scholar
• KENT JM, COPLAN JD, GORMAN JM: Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety. Biol. Psychiatry (1998) 44:812–824.
   PubMed Web of Science ®Google Scholar
• Diagnostic and Statistical Manual of Mental Disorders. 4th ed. American Psychiatric Association, Washington, USA (1994).
   Google Scholar
• Practice guideline for the treatment of patients with panic disorder. Work Group on Panic Disorder. American Psychiatric Association. Am. J. Psychiatry (1998) 155 (Suppl. 5):1–34.
   Google Scholar
• WITTCHEN HU, ZHAO S, KESSLER RC, EATON WW: DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch. Gen. Psychiatry (1994) 51:355–364.
   PubMed Web of Science ®Google Scholar
• DAVIDSON JR, DUPONT RL, HEDGES D, HASKINS JT: Efficacy, safety and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J. Clin. Psychiatry (1999) 60:528–535.
   PubMed Web of Science ®Google Scholar
• BRESLAU N, DAVIS GC, ANDRESKI P, PETERSON E: Traumatic events and posttraumatic stress disorder in an urban population of young adults. Arch. Gen. Psychiatry (1991) 48:216–222.
   PubMed Web of Science ®Google Scholar
• RESNICK HS, KILPATRICK DG, DANSKY BS, SAUNDERS BE, BEST CL: Prevalence of civilian trauma and posttraumatic stress disorder in a representative national sample of women. J Consult. Clin. Psycho]. (1993) 61:984–991.
   PubMed Web of Science ®Google Scholar
• DAVIDSON JRT, MARCH JS: Traumatic stress disorders. In: Psychiatry 1st ed Tasman A, Kay J, Lieberman JA (Eds.), W.B. Saunders Company, Philadelphia, USA (1997):1085–1099.
   Google Scholar
• SOLOMON SD, DAVIDSON JR: Trauma: prevalence, impairment, service use and cost. J. Clin. Psychiatry (1997) 58 (Supp1.9):5–11.
   Google Scholar
• FRIEDMAN MJ: Current and future drug treatment for posttraumatic stress disorder patients. Psychiatric Ann. (1998) 28:461–468.
   Web of Science ®Google Scholar
• DAVIDSON JR, MALIK ML, SUTHERLAND SN: Response characteristics, to antidepressants and placebo in post-traumatic stress disorder. Int. Clin. Psychopharmacol. (1997) 12:291–296.
   PubMedGoogle Scholar
• HERTZBERG MA, FELDMAN ME, BECKHAM JC, DAVIDSON JR: Trial of trazodone for posttraumatic stress disorder using a multiple baseline group design. J. Clin. Psychopharmacol. (1996) 16:294–298.
   PubMed Web of Science ®Google Scholar
• WELLS GB, CHU C, JOHNSON R et al.: Buspirone in thetreatment of post-traumatic stress disorder. J. Clin. Psychiatry (1991) 55:517–522.
   Google Scholar
• YEHUDA R, GILLER EL, SOUTHWICK SM, LOWY MT, MASON JW: Hypothalamic-pituitary-adrenal dysfunc-tion in posttraumatic stress disorder. Biol. Psychiatry (1991) 30:1031–1048.
   PubMed Web of Science ®Google Scholar
• POST RM, WEISS SRB, SMITH MA: Sensitization andkindling: implications for the evolving neural substrate of PTSD. In: Neurobiological and Clinical Consequences of Stress: From Normal Adaptation to PTSD. Friedman MJ, Charney DS, Deutch AY (Eds.), Lippincott-Raven Press, Philadelphia, USA (1995):203–224.
   Google Scholar
• FRIEDMAN MJ, SOUTHWICK SM: Towards pharmaco-therapy for PTSD. In: Neurobiological and Clinical Consequences of Stress: From Normal Adaptation to PTSD. Friedman MJ, Charney DS, Deutch AY (Eds.), Lippincott-Raven Press, Philadelphia, USA (1995):465–481.
   Google Scholar
• GOODMAN WK, PRICE LH, RASMUSSEN SA et al.: TheYale-Brown Obsessive Compulsive Scale. I. Develop-ment, use and reliability. Arch. Gen. Psychiatry (1989) 46:1006–1011.
   PubMed Web of Science ®Google Scholar
• KARNO M, GOLDING JM, SORENSON SB, BURNAM MA:The epidemiology of obsessive-compulsive disorder in five US communities. Arch. Gen. Psychiatry (1988) 45:1094–1099.
   PubMed Web of Science ®Google Scholar
• HOLLANDER E, STEIN D, BROATCH J: A pharma-coeconomic and quality of life study of OCD. Scientific Abstracts of the 34th Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico, December 11-15 (1995):155.
   Google Scholar
• ELLINGROD VL: Pharmacotherapy of primary obsessive-compulsive disorder: review of the litera-ture. Pharmacotherapy (1998) 18:936–960.
   PubMedGoogle Scholar
• VAN AMERINGEN M, MANCINI C, STYAN G, DONISON D: Relationship of social phobia with other psychiatric illness. J. Affect. Disord. (1991) 21:93–99.
   PubMed Web of Science ®Google Scholar
• LADER M: The clinical relevance of treating social phobia. J. Affect. Disord. (1998) 50\(Suppl. 1):S29–34.
   Google Scholar
• Lydiard RB: The role of drug therapy in social phobia. J. Affect. Disord. (1998) 50\(Suppl. 1):S35–39.
   Google Scholar
• ANTONY MH, BARLOW DH: Social and specific phobias. In: Psychiatry. 1st ed Tasman A, Kay J, Lieberman JA (Eds.), W.B. Saunders Company, Philadelphia, USA (1997)1037–1059.
   Google Scholar
• HENNINGER GR: Special challenges in the investigationof the neurobiology of mental illness. In: Neurobiology of, Mental Illness. Charney DS, Nestler EJ, Bunney BS (Eds.), Oxford University Press, New York, USA (1999):89–99.
   Google Scholar
• GOA KL, WARD A: Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an amdolytic. Drugs (1986) 32:114–129.
   Google Scholar
• TAYLOR DP, MOON SL: Buspirone and related compounds as alternative amdolytics. Neuropeptides (1991) 19(Suppl.):15–19.
   Google Scholar
• LECRUBIER Y, PUECH AJ, AZCONA A, BAILEY PE, LATASTE X: A randomized double-blind placebo-controlled study of tropisetron in the treatment of outpatients with generalized anxiety disorder. Psycho-pharmacology (1993) 112:129–133.
   PubMed Web of Science ®Google Scholar
• KRAMER MS, CUTLER NR, BALLENGER JC et al.: A placebo-controlled trial of L-365,260, a CCKB antago-nist, in panic disorder. Biol. Psychiatry (1995) 37:462–466.
   PubMed Web of Science ®Google Scholar
• HOGG S: A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacol. Biochem. Behav. (1996) 54:21–30.
   PubMed Web of Science ®Google Scholar
• GRIEBEL G: 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacol Ther. (1995) 65:319–395.
   PubMed Web of Science ®Google Scholar
• ••Exhaustive review of serotonergic agents used in animalanxiety models that also addresses difficulties in evaluating the validity of such models.
   Google Scholar
• FILE SE: Behavioural detection of anxiolytic action. In: Experimental Approaches to Anxiety and Depression. Elliot JM, Heal DJ, Marsden CA (Eds.), J Wiley, Chichester, UK (1992):25–44.
   Google Scholar
• RODGERS RJ, DALVI A: Anxiety, defence and the elevated plus-maze. NeuroscL Biobehav. Rev. (1997) 21:801–810.
   PubMed Web of Science ®Google Scholar
• GRAEFF FG: Serotonergic systems. Psychiatr. Clin. North Am. (1997) 20:723–739.
   PubMed Web of Science ®Google Scholar
• OLIVIER B, SOUDIJN W, VAN WIJNGAARDEN I: The 5-HT1A receptor and its ligands: structure and function. Prog. Drug Res. (1999) 52:103–165.
   PubMedGoogle Scholar
• DEN BOER JA, WESTENBERG HG: Behavioral, neuroen-docrine and biochemical effects of 5- hydroxytrypto-phan administration in panic disorder. Psychiatry Res. (1990) 31:267–278.
   PubMedGoogle Scholar
• CHARNEY DS, BREMNER JD: The neurobiology of anxiety disorders. In: Neurobiology of Mental Illness. Charney DS, Nestler EJ, Bunney BS (Eds.), Oxford University Press, New York, USA (1999):494–517.
   Google Scholar
• •Recent review of neurobiological findings in anxiety disorders.
   Google Scholar
• SOUTHWICK SM, KRYSTAL JH, BREMNER JD et al.: Noradrenergic and serotonergic function in posttrau-matic stress disorder. Arch. Gen. Psychiatry (1997) 54:749–758.
   PubMed Web of Science ®Google Scholar
• ARORA RC, FICHTNER CG, O'CONNOR F, CRAYTON JW:Paroxetine binding in the blood platelets of post-traumatic stress disorder patients. Life ScL (1993) 53:919–928.
   PubMedGoogle Scholar
• NAYEEM N, GREEN TP, MARTIN IL, BARNARD EA: Quater-nary structure of the native GABAA receptor determined by electron microscopic image analysis. J. Neurochem. (1994) 62:815–818.
   PubMed Web of Science ®Google Scholar
• MEHTA AK, TICKU MK: An update on GABAA receptors. Brain Res. Rev. (1999) 29:196–217.
   PubMed Web of Science ®Google Scholar
• ••Recent, extensive review of the structure, function andpharmacology of GABAA receptors.
   Google Scholar
• WHITING PJ, MCKERNAN RM, WAFFORD KA: Structureand pharmacology of vertebrate GABAA receptor subtypes. Int. Rev. Neurobiol. (1995) 38:95–138.
   PubMed Web of Science ®Google Scholar
• WISDEN W, LAURIE DJ, MONYER H, SEEBURG PH: Thedistribution of 13 GABAA receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon. j Neurosci. (1992) 12:1040–1062.
   PubMed Web of Science ®Google Scholar
• LAURIE DJ, SEEBURG PH, WISDEN W: The distribution of13 GABAA receptor subunit mRNAs in the rat brain. II. Olfactory bulb and cerebellum. J. Neurosci. (1992) 12:1063–1076.
   Google Scholar
• WOODS SW, CHARNEY DS, SILVER JM, KRYSTAL JH, HENINGER GR: Behavioral, biochemical and cardiovas-cular responses to the benzodiazepine receptor antagonist flumazenil in panic disorder. Psychiatry Res. (1991) 36:115–127.
   PubMedGoogle Scholar
• NUTT DJ, GLUE P, LAWSON C, WILSON S: Flumazenil provocation of panic attacks. Evidence for altered benzodiazepine receptor sensitivity in panic disorder. Arch. Gen. Psychiatry (1990) 47:917–925.
   Google Scholar
• ROY-BYRNE PP, LEWIS N, VILLACRES E et al.: Preliminaryevidence of benzodiazepine subsensitivity in panic disorder. Biol. Psychiatry (1989) 26:744–748.
   PubMedGoogle Scholar
• ROY-BYRNE P, WINGERSON DK, RADANT A, GREENBLATT DJ, COWLEY DS: Reduced benzodiazepine sensitivity in patients with panic disorder: comparison with patients with obsessive-compulsive disorder and normal subjects. Am. J. Psychiatry (1996) 153:1444–1449.
   PubMed Web of Science ®Google Scholar
• SCHLEGEL S, STEINERT H, BOCKISCH A, HAHN K, SCHLOESSER R, BENKERT 0: Decreased benzodiazepine receptor binding in panic disorder measured by IOMAZENIL-SPECT. A preliminary report. Eur. Arch. Psychiatry Clin. Neurosci. (1994) 244:49–51.
   PubMed Web of Science ®Google Scholar
• KUIKKA JT, PITKANEN A, LEPOLA U et al: Abnormalregional benzodiazepine receptor uptake in the prefrontal cortex in patients with panic disorder. Nucl. Med. Commun. (1995) 16:273–280.
   PubMed Web of Science ®Google Scholar
• LYDIARD RB, BALLENGER JC, RICKELS K: A double-blindevaluation of the safety and efficacy of abecarnil, alprazolam and placebo in outpatients with general-ized anxiety disorder. Abecarnil Work Group. J. Clin. Psychiatry (1997) 58 (Suppl. 11) :11–18.
   Google Scholar
• POLLACK MH, WORTHINGTON JJ, MANFRO GG, OTTOMW, ZUCKER BG: Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone. j Clin. Psychiatry (1997) 58\(Suppl. 10:19–23.
   Google Scholar
• AUFDEMBRINKE B: Abecarnil, a new beta-carboline, in the treatment of anxiety disorders. Br. J. Psychiatry Suppl. (1998) 34:55–63.
   Google Scholar
• BETANCUR C, AZZI M, ROSTENE W: Nonpeptide antago-nists of neuropeptide receptors: tools for research and therapy. Trends Pharmacol. ScL (1997) 18:372–386.
   PubMedGoogle Scholar
• •A discussion of the issues involved in creating and using non-peptide antagonists of neuropeptide receptors.
   Google Scholar
• HOLSBOER F: The rationale for corticotropin-releasing hormone, receptor (CRH-I) antagonists to treat depression and anxiety. J. Psychiatr. Res. (1999) 33:181–214.
   PubMed Web of Science ®Google Scholar
• ••Extensive review of the role of CRH in psychiatric disorders.
   Google Scholar
• ARBORELIUS L, OWENS MJ, PLOTSKY PM, NEMEROFF CB: The, role of corticotropin-releasing factor in depres-sion and anxiety disorders. J. Endocrinof (1999) 160:1–12.
   PubMed Web of Science ®Google Scholar
• GRIEBEL G: Is there a future for neuropeptide receptor ligands, in the treatment of anxiety disorders? Pharmacol. Ther. (1999) 82:1–61.
   Google Scholar
• ••Exhaustive review of neuropeptides and related agentsconsidered relevant to anxiety disorders.
   Google Scholar
• VAN BOCKSTAELE EJ, COLAGO EE, VALENTINO RJ: Corticotropin-releasing factor-containing axon terminals synapse onto catecholamine dendrites and may presynaptically modulate other afferents in the rostral pole of the nucleus locus coeruleus in the rat brain. J. Comp. Neurol. (1996) 364:523–534.
   PubMed Web of Science ®Google Scholar
• VALENTINO RJ, WEHBY RG: Corticotropin-releasing factor: evidence for a neurotransmitter role in the locus ceruleus during hemodynamic stress. Neuroen-docrinology (1988) 48:674–677.
   PubMed Web of Science ®Google Scholar
• BUTLER PD, WEISS JM, STOUT JC, NEMEROFF CB: Corticotropin-releasing factor produces fear-enhancing and behavioral activating effects following infusion into the locus coeruleus. J. Neurosci. (1990) 10:176–183.
   PubMedGoogle Scholar
• PANDE AC: Lack of efficacy of a cholecystokinin-B antagonist in anxiety disorders. Biol. Psychiatry (1997) 42:11–19.
   Google Scholar
• ADAMS JB, PYKE RE, COSTA J et al: A double-blind,placebo-controlled study of a CCKB receptor antago-nist, CI-988, in patients with generalized anxiety disorder. J. Gun. Psychopharmacol. (1995) 15:428–434.
   Google Scholar
• DUMONT Y, FOURNIER A, ST-PIERRE S, QUIRION R: Characterization of neuropeptide Y binding sites in rat brain membrane preparations using [1251] [Leu31,Pro34]peptide YY and [1251]peptide YY3-36 as selective Y1 and Y2 radioligands. J. Pharmacol. Exp. Ther. (1995) 272:673–680.
   PubMed Web of Science ®Google Scholar
• BOULENGER JP, JERABEK I, JOLICOEUR FB, LAVALLEE YJ,LEDUC R, CADIEUX A: Elevated plasma levels of neuropeptide Y in patients with panic disorder. Am. J. Psychiatry (1996) 153:114–116.
   PubMed Web of Science ®Google Scholar
• OTSUKA M, YOSHIOKA K: Neurotransmitter functionsof mammalian tachykinins. Physiol. Rev. (1993) 73:229–308.
   PubMed Web of Science ®Google Scholar
• MAGGI CA: The mammalian tachykinin receptors. Gen. Pharmacol,. (1995) 26:911–944.
   PubMedGoogle Scholar